
    interim analysis found study had achieved primary objective
  
['age-related macular degeneration (amd)', 'macular degeneration', 'exudative age-related macular degeneration', 'amd', 'macular degeneration, age-related, 10', 'eye diseases', 'retinal degeneration', 'retinal diseases']
['x-82', 'anti-vegf', 'placebo']

        Inclusion Criteria:

          -  Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in
             one or both eyes for at least 6 months prior to joining the study and has required at
             least two prior injections of intravitreal (ivt) anti-VEGF at intervals of not greater
             than 6 weeks for the past two injections in the eye that is selected to be the study
             eye.

          -  Must have demonstrated a reduction in macular fluid or macular thickness in the study
             eye 14 days following an anti-VEGF injection at Screening Visit 1

          -  Early Treatment Diabetic Retinopathy (ETDRS) Best Corrected Visual Acuity (BCVA) of 25
             letters (20/320) or better in both eyes

        Exclusion Criteria:

          -  Previous vitrectomy to the study eye within 30 days of Screening Visit 1

          -  Choroidal neovascularization (CNV) due to causes other than AMD

          -  Proliferative diabetic retinopathy in either eye
      